Fig. 1From: Plasma interleukin-23 and circulating IL-17A+IFNγ+ ex-Th17 cells predict opposing outcomes of anti-TNF therapy in rheumatoid arthritisBaseline blood profiles associated with response to anti-TNF therapy. A Presence of plasma IL-23 (IL-23+) at baseline and response to anti-TNF therapy. Depicted is the frequency of poor response with 95% confidence interval error bars in parenthesis for only IL-23+ participants (n=20): 75% (51–91%); and for only IL-23− participants (n=73): 49% (37–61%). A significantly higher proportion of IL-23+ participants at baseline are poor responders (p = 0.041). B Circulating IL-17A+IFNγ+ ex-Th17 cells at baseline and response to anti-TNF therapy. The frequency of IL-17A+IFNγ+ ex-Th17 cells is significantly higher in good responders (p=0.023). Data are expressed as the median and interquartile range with 5% and 95% percentiles indicatedBack to article page